Using a zebrafish xenograft tumor model to compare the efficacy and safety of VEGFR-TKIs

• Published in: Journal of cancer research and clinical oncology 2023-08, Vol.149 (9), p.5975-5987
• Main Authors: Wanting, Hou, Jian, Zhong, Chaoxin, Xiao, Cheng, Yi, Chengjian, Zhao, Lin, Zhou, Dan, Cao
• Format: Article
• Language: English
• Subjects: Animals; Axitinib - therapeutic use; Cancer Research; Danio rerio; Disease Models, Animal; Edema; Edema - complications; Edema - drug therapy; Heart rate; Hematology; Heterografts; Humans; Internal Medicine; Lethal dose; Medicine; Medicine & Public Health; Neoplasms - complications; Neoplasms - drug therapy; Oncology; Protein Kinase Inhibitors - pharmacology; Protein Kinase Inhibitors - therapeutic use; Protein-tyrosine kinase; Protein-Tyrosine Kinases - therapeutic use; Receptors, Vascular Endothelial Growth Factor - therapeutic use; Toxicity; Tumor cells; Tumors; Vascular endothelial growth factor; Vascular Endothelial Growth Factor A; Vascular endothelial growth factor receptors; Xenografts; Zebrafish
• ISSN: 0171-5216; 1432-1335
• DOI: 10.1007/s00432-022-04560-7

Purpose We constructed a zebrafish xenograft tumor model to compare and quantify the antiangiogenic efficacy and safety of nine vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKIs), axitinib, lenvatinib, pazopanib, apatinib, cabozantinib, sunitinib, semaxanib, sorafenib, and regorafenib, in parallel. Methods CT26 and GL261 tumor cells were implanted into the perivitelline space of Tg (flk1: eGFP) zebrafish to construct a xenograft tumor model. VEGFR-TKIs’ antiangiogenic efficacy was quantified using AngioTool software, and the median effective dose (ED50) was calculated. The toxicity was evaluated by calculating the median lethal dose (LD50) and gross morphological changes. Cardiac toxicity was further assessed by heart rate, heart rhythm, the distance between the sinus venosus (SV) and bulbus arteriosus (BA), and pericardial edema. Results Using the zebrafish xenograft tumor model, we found that all nine VEGFR-TKIs exhibited antiangiogenic abilities, but the effectiveness of semaxanib was worse than that of other VEGFR-TKIs. Meanwhile, the zebrafish toxicity assay showed that all tested VEGFR-TKIs were associated with cardiac-related toxicity, especially apatinib and axitinib, which caused serious pericardial edema in zebrafish at relatively low concentrations. A narrow therapeutic window was found for most VEGFR-TKIs, and the simultaneous occurrence of toxic effects of semaxanib was recognized. Conclusion Our findings showed the potential of using a zebrafish xenograft tumor model to accelerate VEGFR-TKI screening and further the development of more efficient and less toxic VEGFR-TKIs.